The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” ...

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Kymera Therapeutics raises $250.8M in public offering to advance its innovative degrader medicines for immunological diseases.

TotalEnergies SE (EPA:TTEF) revealed on Friday that it has acquired a 25% interest in Block 53 offshore Suriname from Spain’s Moeve, formerly CEPSA.

Boeing is entering a new phase of recovery that could support a market reassessment of its stock, according to analysts at Redburn.